Psoriasis is a skin disease that can negatively impact on patients' psychosocial well-being. It affects millions of people worldwide. The overall economic burden (meaning the cost to the economy) of psoriasis is severe; however, no study has fully assessed it due to a lack of comparable data from different countries. This study looked at work productivity loss (WPL) and indirect costs, using the same methods and at the same point in time in six countries (the USA, France, Germany, Spain, the UK and Italy). Work productivity loss (WPL) takes into account absenteeism (time missed from work due to a disease, in this case psoriasis) and presenteeism (reduced productivity due to psoriasis while at work). Associated indirect costs are a calculation of how much this WPL costs in financial terms. The study also looked at whether WPL was associated with the severity of patients' psoriasis across these countries. The researchers found that work productivity was progressively more affected with increasing psoriasis severity, broadly meaning that the more severe the psoriasis, the greater the work productivity loss. This confirms the relationship between disease severity and its economic burden. This study contributes to our understanding of the global economic burden of psoriasis by demonstrating that WPL correlates with severity of psoriasis and health-related quality of life in people who are employed. Consequently, therapies that effectively treat psoriasis and improve health-related quality of life are likely to have a positive impact on WPL and, in turn, the considerable economic burden of psoriasis. Linked Article: Villacorta et al. Br J Dermatol 2020; 183:548-558.